|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Autonomic and peptide innervations of human nasal mucosa显示文摘 | Hauser-Kronberger C Hacker GW Muss W | 1993 | Acta otolaryngol(stockh)1993，113，3： | 1 |
| 2 | Autonomic and peptidergic innervation of human nasal mucosa显示文摘 | Hauser-Kronberger C Hacker GW Muss W | 1993 | Acta Otolaryngol(Stockh)1993，113，3： | 1 |
| 3 | Shallow mtDNA coalescence in Atlantic pygmy angelfishes (genus Centropyge) indicatcs a recent invasion from the Indian ocean显示文摘 | Bowen B W Muss A Rocha L A | 2006 | J Hered2006，97，1： | 1 |
| 4 | Microbial metabolism of halo aromatic:isolation and properties of a chlorobenzene-degrading显示文摘 | Knack Muss H J | 1984 | Appl Environ Microbiol1984，47，2： | 1 |
| 5 | Autonomic and peptidergic innervation of numan mucosa显示文摘 | HANSER KRONBERGER C HACKER GW MUSS W | 1993 | Acta Otolaryngol1993，113，： | 1 |
| 6 | Autonomic and peptidergic innervation of human nasalmucosa显示文摘 | Hauser-Kronberger C Hacker C W Muss W | 1993 | Acta Oto-laryngologica1993，113，3： | 1 |
| 7 | Silver acetate autometallography:an alternative enhancement technique for immunogold-silver staining (IGSS) and silver amplification of gold,silver,mercury and zinc in tissues显示文摘 | Hacker G W Grimelius L Danscher G Bernatzky G Muss W Adam H Thurner J | 1988 | JHistotechnol1988，11，： | 1 |
| 8 | Shallow mtDNA coalescence in Atlantic pygmy angclfishes (genus Centropyge) indicates a recent invasion from the Indian Ocean 显示文摘 | Bowen B W Muss A Rocha L A | 2006 | J Hered2006，97，1： | 1 |
| 9 | Histopathology of human corneas after amniotic membrane and limbal stem cell transplantation for severe chemical bum 显示文摘 | STOIBER J MUSS W H POHIA-GUBO G | 2002 | Cornea2002，21，5： | 1 |
| 10 | Impact of community-based exercise program participation on aerobic capacity in women with and without breast cancer显示文摘BACKGROUND Evidence for exercise as an efficacious strategy to improve aerobic capacity of breast cancer survivors(BCS)has come largely from intervention studies conducted in laboratory settings.There is an increasing need to translate to community-type settings,but the efficacy of those interventions using gold standard evaluation is not well-established.AIM To investigate whether similar improvement in aerobic capacity(maximal oxygen consumption[VO2])measured with gold standard testing can be achieved through a community-based setting in BCS.METHODS A peak cardiopulmonary exercise test(VO2peak),6-min walk test(6MWT),and timed up and go test(TUG)were assessed pre-and post-16 wk of progressive intensity aerobic and strength training exercise at a community center.RESULTS The sample consisted of 31 early BCS(<1 year since treatment completion)and 15 controls(CTLs).Both groups significantly improved VO2peak(+1.2 mL/kg/min;P=0.030),6MWT(+35 meters;P<0.001),and TUG(-0.44 s;P<0.01)following training.Both groups improved peak cycling power during the cardiopulmonary exercise test with BCS improving by+10 watts more than the CTLs(P=0.020).Average exercise attendance was 71%(34 of 48 possible days),but compliant days averaged only 60%of total days for aerobic,and<40%for strength in both groups.CONCLUSION Community-based exercise programs can be an effective strategy to improve aerobic capacity and physical function for early-stage BCS but potentially not to the same extent observed in laboratory-based randomized controlled trials.Further research is needed to explore barriers and facilitators of exercise engagement in community-based centers to maximize training benefits for adults with cancer. | Jordan T Lee Chad W Wagoner Stephanie A Sullivan Dean J Amatuli Kirsten A Nyrop Erik D Hanson Lee Stoner Brian C Jensen Hyman B Muss Claudio L Battaglini | 2021 | World Journal of Clinical Oncology2021，12，6： | 0 |
| 11 | Competing risks of death in younger and older postmenopausal breast cancer patients显示文摘AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramuscular injections monthly. Event-free survival was the primary endpoint of MA.14; at median 7.9 years, the tamoxifen+octreotide and tamoxifen arms had similar event-free survival(P = 0.62). Overall survival was a secondary endpoint, and the two trial arms also had similar overall survival(P = 0.86). We used the median 9.8 years follow-up to examine by intention-to-treat, the multivariate time-to-breast cancer-specific(Br Ca) and other cause(OC) mortality with log-normal survival analysis adjusted by treatment and stratification factors. We tested whether baseline factors including Insulin-like growth factor 1(IGF1), IGF binding protein-3, C-peptide, body mass index, and 25-OH vitamin D were associated with(1) all cause mortality, and if so; and(2) cause-specific mortality. We also fit step-wise forward cause-specific adjusted models.RESULTS: The analyses were performed on 329 patients allocated tamoxifen and 329 allocated tamoxifen+octreotide. The median age of MA.14 patients was 60.1 years: 447(82%) < 70 years and 120(18%) ≥ 70 years. There were 170 deaths: 106(62.3%) BrC a; 55(32.4%) OC, of which 24 were other malignancies, 31 other causes of death; 9(5.3%) patients with unknown cause of death were excluded from competing risk assessments. BrC a and OC deaths were not significantly different by treatment arm(P = 0.40): tamoxifen patients experienced 50 BrC a and 32 OC deaths, while tamoxifen + octreotide patients experienced 56 Br Ca and 23 OC deaths. Proportionately more deaths(P = 0.004) were from BrC a for patients< 70 years, where 70% of deaths were due to Br Ca, compared to 54% for those ≥ 70 years of age. The proportion of deaths from OC increased with increasing body mass index(BMI)(P = 0.02). Higher pathologic T and N were associated with more BrC a deaths(P < 0.0001 and 0.002, respectively). The cumulative hazard plot for Br Ca and OC mortality indicated the concurrent accrual of both types of death throughout followup, that is the existence of competing risks of mortality. MA.14 therapy did not impact mortality(P = 0.77). Three baseline patient and tumor characteristics were differentially associated with cause of death: older patients experienced more OC(P = 0.01) mortality; patients with T1 tumors and hormone receptor positive tumors had less BrC a mortality(respectively, P = 0.01, P = 0.06). Additionally, step-wise cause-specific models indicated that patients with node negative disease experienced less BrC a mortality(P = 0.002); there was weak evidence that, lower C-peptide(P = 0.08) was associated with less BrC a mortality, while higher BMI(P = 0.01) was associated with worse OC mortality.CONCLUSION: We demonstrate here a new paradigm of simultaneous testing of therapeutics directed at multiple diseases for which postmenopausal women are concurrently at risk. Octreotide LAR did not significantly impact breast cancer or other cause mortality, although different baseline factors influenced type of death. | Judy-Anne W Chapman Kathleen I Pritchard Paul E Goss James N Ingle Hyman B Muss Susan F Dent Ted A Vandenberg Brian Findlay Karen A Gelmon Carolyn F Wilson Lois E Shepherd Michael N Pollak | 2014 | World Journal of Clinical Oncology2014，5，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员